AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Specific Antibody-Drug Conjugate Synthesis
Yutaka Matsuda(Ajinomoto (United States)), Shigeo Hirasawa(Suzuki (Japan)), Akira Nakayama(Shizuoka University), Brian A. Mendelsohn(Seagen (United States)), Noriko Hatada(Suzuki (Japan)), Yuichi Nakahara(Suzuki (Japan)), Takuya Seki(Suzuki (Japan)), Kazutoshi Takahashi(Suzuki (Japan)), Yuta Endo(Fukushima Medical University), Kazutaka Shimbo(Suzuki (Japan)), Kei Yamada(Kurume University), Tatsuya Okuzumi(Suzuki (Japan)), Tomohiro Fujii(Suzuki (Japan)), Natsuki Shikida(Suzuki (Japan))
Cited by 2
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296